BLFS — BioLife Solutions, Inc.

BioLife Solutions Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $27.5 million, up 25% year-over-year.
• Adjusted EBITDA: $6.2 million, representing 22% of revenue, an increase of approximately 15% from the previous year.
• GAAP Gross Margin: 64%, down from 67% in Q1 2025.
• Adjusted Gross Margin: 64%, down from 68% year-over-year.
• GAAP Operating Income: $27,000, compared to an operating loss of $0.5 million in Q1 2025.
• GAAP Net Income: $1.2 million ($0.02 per share), up from $0.3 million ($0.01 per share) in the prior year.
• Cash and Marketable Securities: $111.5 million as of March 31, 2026, down from $120.2 million at year-end 2025.

2. Strategic Updates and Business Highlights:

• Product Portfolio Strength: Revenue growth driven primarily by the biopreservation media (BPM) franchise, which constitutes over 85% of total revenue.
• Market Share: BioLife maintains a dominant position in the BPM market with over 70% share in commercially sponsored clinical trials.
• Expansion Plans: Focus on cross-selling additional products (e.g., CellSeal Vials, hPL) to existing BPM customers, aiming to increase revenue per dose significantly.
• R&D Investments: Increased R&D expenses due to the establishment of a new Center of Excellence and ongoing projects, including the PanTHERA product set for a Q4 launch.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Reiterated expectation of $112.5 million to $115 million, reflecting 17% to 20% growth.
• Gross Margin Expectations: Anticipated to remain in the mid-60s, with potential improvements as bag yield issues are resolved.
• GAAP Net Income: Expected to achieve full-year positive GAAP net income for the first time in several years.

4. Bad News, Challenges, or Points of Concern:

• Declining Margins: Year-over-year declines in gross margins attributed to a shift in product mix towards lower-margin bags and manufacturing yield issues.
• Operational Challenges: The ongoing bag yield issue is a key operational priority, with expectations for resolution impacting future margins.
• Market Dynamics: While the company is well-positioned, the reliance on larger, well-capitalized customers may limit growth from early-stage biotech firms, which are more sensitive to funding fluctuations.

5. Notable Q&A Insights:

• Bag Yield Issues: Management confirmed that bags have lower margins than bottles and are addressing yield problems with customer collaboration, expecting improvements by late 2026.
• Product Development: The PanTHERA product launch is on track for Q4 2026, with cross-selling efforts gaining momentum, albeit at a slower pace due to validation processes.
• Biotech Funding Impact: Management indicated that while biotech funding recovery is underway, it primarily affects early-stage customers, with little impact on revenue from established firms.
• Allogeneic Cell Therapy: The market for allogeneic therapies is expected to grow, but significant revenue impact is still a couple of years away.
• CryoCase Product Recognition: The CryoCase received a Best In Show award, indicating strong interest and ongoing validations, with expectations for commercial traction in the latter half of 2026.

Overall, BioLife Solutions reported strong revenue growth and operational progress in Q1 2026, while also addressing challenges related to margin pressures and product mix. The company remains optimistic about its long-term growth trajectory within the cell and gene therapy market.